Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

Research output: Contribution to journalLetterpeer-review

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)718-720
Number of pages3
JournalHematological Oncology
Volume36
Issue number4
DOIs
StatePublished - Oct 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this